Tissues from melanoma tumors (n = 219) were obtained from the Department of Oncology at Lund University. After surgical removal of the tumors, all biopsies were snap frozen in liquid nitrogen and further stored at ultra-low temperature for later experimental use. Frozen tissues were homogenized using a TissueLyser (Qiagen) and DNA and RNA extracts were isolated using the AllPrep kit (Qiagen). To confirm good RNA quality, all extracts were analyzed on an Agilent Bioanalyzer 2100 (Agilent) and only samples with a RIN value larger than 6 was included in the study. DNA from blood samples was extracted using the DNeasy Blood and Tissue kit (Qiagen).
p-value <0.01 were kept if present in minimum 80% of the samples. Of the 13955 probes retained, 13744 probes corresponded to RefSeq features. These RefSeq features mapped to 11051 unique genes and the most varying probe for each gene was kept in the data. In order to compare gene expression levels across samples, the 11051 probes were mean centered. The centroids from Harbst et al. was used to classify the samples into any of the four recently identify melanoma subtypes [2] . In detail, the nearest centroid classification was used to classify a sample according to the maximum correlation of the sample with the four centroids (Pearson's correlation > 0.2, otherwise set as "unclassified").
Network construction and module expression
A gene co-expression network was created based on correlations between the genes in the data set and five modules of highly connected genes were extracted [3] . Briefly, the initial network was created by connecting nodes (genes) by edges (representing correlations) using a correlation cutoff of 0.6 and only including genes with five or more neighbors. Based on gene ontology analysis and published associations with melanoma-specific tumor biology, the five modules were further entitled as: the micropthalmia-associated transcription factor (MITF) module, including genes such as MITF, MLANA, SILV, CDK2 and ETV5; the cell cycle module, containing genes related to the M phase, such as CCNB2 and CENPF; the stroma module consisting of extracellular matrix-related genes; the immune response module representative of genes enrolled in tumor infiltrating lymphocyte and antigen presentation; and finally also an interferon module consisting of genes responsive of interferon treatment. The resulting gene expression landscape consisting of 394 genes scattered around the five core modules was visualized in Cytoscape ( Figure 1B ) [4] . Module activity scores were calculated for all samples, i.e. mean expression values of all genes representing the particular modules.
SureSelect deep targeting sequencing
Target enrichment design, library preparation and data processing were performed as previously described [5] . Briefly, 1697 frequently mutated cancer-associated genes were selected based on information in the COSMIC database and in the literature to create the SureSelect target enrichment design (5.5 MB coverage by 120 bp-long tiling probes). DNA samples were sheared, end-repaired and given a unique adapter (sample specific barcode) before PCR-amplification. The adapter-ligated fragments were subjected to target enrichment (SureSelect, Agilent), PCR-amplification and sequencing according to Illumina Paired-End Sequencing Library Protocol on a HighSeq2000.
Principal component analysis (PCA)
PCA was used to assess that the variation in the gene expression data was due biological factors and not systematic experimental artifacts. Briefly, PCA functions by reducing the dimensionality of the data by extracting principal components (PCs), i.e. uncorrelated linear vectors further explaining the variation in the data [6] . The PCs are then tested for association with the biological and technical variables to elucidate their impact on the variation in the data. We performed PCA by using the swamp package in R [7] . Results are shown as a heatmap of the associations between PCs and sample annotations ( Figure S4 ).
Immunohistochemistry (IHC)
A subset of the melanoma tumors (n = 59), representing the four major gene expression phenotypes, was selected for immunohistochemistry. After formalin-fixed paraffinembedding, sections (4 µm) were captured and prepared according to standard procedures. Staining was performed using antibodies against MITF (clone: C5, Thermo Fisher), cluster of differentiation 3 (CD3; polyclonal, DAKO) and Ki67 (clone: MIB-1, DAKO), together with the DAKO Envision horseradish peroxidase rabbit/mouse kit system and the Dakocytomation Autostainer (DAKO). Further more, sections were also stained with hematoxylin and eosin (HE) to see structural patterns in the tumor tissues. The data was quantile-normalized between samples using limma [8] , given an offset of 32, capped at 65,000, log-transformed and median-centered over genes. As described in the above section "Gene expression analysis and profiling", samples were classified into any of the four melanoma subtypes using the nearest centroid classification (Pearson's correlation > 0.1, otherwise set as "unclassified"). The 438 available centroid genes found in the data were monitored for batch effects using TCGA's technical annotations.
The gene expression phenotypes and their clinical relevance were evaluated in three independent external datasets obtained from the Gene Expression Ominbus (GEO) repository (GSE50509 [10] ; GSE61992 [11] ; GSE35640 [12] ). In the first study, 21 patients were treated with the BRAF inhibitors (BRAFi) dabrafenib or vemurafenib and evaluated for best objective response (RECIST response, %), progression-free survival (PFS) and screened for resistance mechanisms [10] . In total, 50 specimens were being analyzed in this study including 21 pre-treatment tumors and 29 post-relapse tumors. In the second study, 10 patients were treated with a combination of BRAFi (dabrafenib) and the MEK inhibitor (MEKi) trametinib, and analyzed for similar endpoints as in the prior study. However, gene expression data was only available for 9 patients, thus including 19 specimens in total (9 pre-treatment tumors and 10 post-relapse tumors) [11] . In the third study, 56 patients were analyzed for a pre-treatment gene expression signature predictive of response to MAGE-A3 immunotherapeutic treatment and each patient were assigned a status of responder or non-responder [12] .
Genome-wide gene expression microarray was performed using Illumina Human HT-12 v4 BeadChip arrays (Rizos' and Long's studies) and Affymetrix HG-U133.Plus 2.0 system (Ulloa-Montoya's study) [10, 12] . We performed similar preprocessing of the three already normalized datasets obtained from GEO including addition of a probe presence filter, log2 transformation and KNN-imputation (the latter step was only performed in Rizos' and Long's data). In detail, for samples run on the Illumina platform, we removed probes when less than 80% of the samples had a detection p-value < 0.01, whereas in the Affymetrix data the cutoff was set to 0.1.
Combining datasets using Distance Weighted Discrimination (DWD)
DWD is a well-known classification method, which has also proven to be very useful in microarray datasets to compensate for systematic biases [13, 14] . Based on the findings that molecular portraits are conserved across platforms [15] , we combined our dataset with the above external datasets and applied DWD adjustment before performing nearest centroid classification. Initially, all external datasets were preprocessed as described in the above section "Validation sets" and pairwise analyzes were performed between our dataset and the external datasets (pairwise merging).
Briefly, common centroid genes across the itemed datasets were extracted (Our/Rizos, 260 genes; Our/Long, 281 genes; Our/Ulloa-Montoya, 220 genes). Individual datasets (genes not mean centered) were combined and adjusted in a pairwise manner using the InSilicoMerging package in R calling the "DWD" method. The genes in the pairwise combined and adjusted data were mean centered across all the data and further classified. In order to check for remaining source biases, the data were visualized after DWD adjustment in a multidimensional scaling (MDS) plot ( Figure S5 ) but also analyzed using hierarchical clustering to conclude sample dispersion in a source independent manner (results not shown).
Statistics
All statistical analyzes were performed using R (two-sided tests). Fisher's exact test and Kruskal-Wallis test were performed to compare gene expression phenotypes with clinical characteristics. All survival analyses were made using the survival package in R.
In addition, we performed non-parametric Kruskal-Wallis tests to analyze the module activity scores against clinical characteristics. Abbreviations: NA, not available; SSM, superficial spreading melanoma; NM, nodular melanoma; CI, confidence interval; HR, hazard ratio. 1 Follow up starts at disease progression and ends at melanoma--specific death (=event).
